MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) is advancing toward commercial deployment of its voice-based artificial intelligence platform for detecting drug and alcohol impairment, with a focus on industrial safety applications in South America's mining sector. The company recently appointed Chilean policy specialist Felipe Leyton to lead commercialization efforts in the region, signaling a transition from technology development to field implementation in large enterprise environments.
Leyton brings extensive experience in national drug policy and workplace safety, having helped design and implement Chile's 'Zero Tolerance' alcohol-impaired driving law as part of the country's alcohol prevention framework. He also played a role in establishing Chile's roadside drug testing program introduced in 2019. His appointment reflects MindBio's strategy of aligning technical development with regulatory and industry expertise in markets where impairment detection is closely tied to workplace safety and compliance requirements.
MindBio is a biotechnology company that is commercializing AI prediction technologies for drug and alcohol intoxication detection via voice analysis. The AI prediction model uses over 50 million data points to predict alcohol intoxication with remarkable accuracy, just by using the human voice. The company is developing an enterprise platform including Edge-AI kiosks integrating bespoke hardware and software for the detection of drug and alcohol intoxication using the human voice and AI in a range of enterprise environments including the mining industry, aviation, construction and law enforcement.
The move into South America's mining sector is significant given the region's high safety standards and regulatory focus on impairment detection. With Leyton's background in shaping Chile's drug and alcohol policies, MindBio is well-positioned to navigate local regulations and deploy its technology in one of the world's largest mining markets. The company's platform could potentially reduce workplace accidents by providing non-invasive, real-time impairment screening.
This announcement follows MindBio's broader strategy to expand its AI solutions beyond initial pilot programs. The company has been working on refining its voice analysis technology to ensure high accuracy and reliability in various environmental conditions, such as those found in mining operations. The deployment in South America could serve as a proof of concept for other industrial sectors globally.
For more information on MindBio Therapeutics and its AI platform, visit the company's newsroom at https://ibn.fm/MBQIF. The full article detailing this development can be accessed at https://ibn.fm/JBNVq.
